{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:51:26Z","timestamp":1777427486040,"version":"3.51.4"},"reference-count":44,"publisher":"Becaris Publishing Limited","issue":"1","funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>Compare weight changes between people living with HIV-1 (PLWH) at high risk of weight gain (females, Blacks or Hispanics) switching from an integrase strand transfer inhibitor (INSTI) to a protease inhibitor (PI) or another INSTI.<jats:bold>Materials &amp; methods:<\/jats:bold>Mean weight changes from pre-switch to up-to-12\u00a0months post-switch were retrospectively compared between PLWH switching to a PI or INSTI.<jats:bold>Results:<\/jats:bold>356 PLWH were eligible. At 9- and 12-month post-switch, weight increases were observed for INSTI (weight: +1.55\u00a0kg and +1.59\u00a0kg), while decreases were observed for PI (-0.23\u00a0kg and -1.59\u00a0kg); differences between cohorts widened over time.<jats:bold>Conclusion:<\/jats:bold>These data suggest that switching off an INSTI may be a management tool to mitigate or reverse weight gain.<\/jats:p>","DOI":"10.2217\/cer-2022-0147","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T14:50:56Z","timestamp":1669733456000},"source":"Crossref","is-referenced-by-count":6,"title":["Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors"],"prefix":"10.57264","volume":"12","author":[{"given":"Prina","family":"Donga","sequence":"first","affiliation":[{"name":"Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 1190 avenue des Canadiens-de-Montr\u00e9al, Suite 1500, Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 1190 avenue des Canadiens-de-Montr\u00e9al, Suite 1500, Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahim K","family":"Bookhart","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Anderson","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maude","family":"Vermette-Laforme","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 1190 avenue des Canadiens-de-Montr\u00e9al, Suite 1500, Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 1190 avenue des Canadiens-de-Montr\u00e9al, Suite 1500, Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 1190 avenue des Canadiens-de-Montr\u00e9al, Suite 1500, Montr\u00e9al, QC H3B 0G7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3851\/IMP1301","article-title":"Efficacy and safety of darunavir\/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96","volume":"14","author":"Arasteh K","year":"2009","unstructured":"Arasteh K, Yeni P, Pozniak A Efficacy and safety of darunavir\/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 14(6), 859\u2013864 (2009).","journal-title":"Antivir. Ther."},{"issue":"2","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e3182973966","article-title":"Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care","volume":"64","author":"Farnham PG","year":"2013","unstructured":"Farnham PG, Gopalappa C, Sansom SL Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J. Acquir. Immune Defic. Syndr. 64(2), 183\u2013189 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren JD","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373(9), 795\u2013807 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/QAD.0000000000001417","article-title":"Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"31","author":"Lifson AR","year":"2017","unstructured":"Lifson AR, Grund B, Gardner EM Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS 31(7), 953\u2013963 (2017).","journal-title":"AIDS"},{"issue":"12","key":"e_1_3_5_7_2","first-page":"1525","article-title":"Comorbidities among US patients with prevalent HIV infection \u2013 a trend analysis","volume":"216","author":"Gallant J","year":"2017","unstructured":"Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection \u2013 a trend analysis. J. Infect. Dis. 216(12), 1525\u20131533 (2017).","journal-title":"J. Infect. Dis."},{"issue":"6","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/dc06-2544","article-title":"Effect of BMI on lifetime risk for diabetes in the U.S","volume":"30","author":"Narayan KM","year":"2007","unstructured":"Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 30(6), 1562\u20131566 (2007).","journal-title":"Diabetes Care"},{"issue":"17","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"e011825","DOI":"10.1161\/JAHA.118.011825","article-title":"Association of concurrent changes in metabolic health and weight on cardiovascular disease risk: a nationally representative cohort study","volume":"8","author":"Bae YS","year":"2019","unstructured":"Bae YS, Choi S, Lee K Association of concurrent changes in metabolic health and weight on cardiovascular disease risk: a nationally representative cohort study. J. Am. Heart Assoc. 8(17), e011825 (2019).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe JR","year":"2016","unstructured":"Koethe JR, Jenkins CA, Lau B Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res. Hum. Retroviruses 32(1), 50\u201358 (2016).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"e_1_3_5_11_2","article-title":"Changes in body mass index over time in persons with and without HIV","author":"Silverberg M","year":"2020","unstructured":"Silverberg M, Leyden W, Alexeef S Changes in body mass index over time in persons with and without HIV. 23rd International AIDS Conference (2020).","journal-title":"23rd International AIDS Conference"},{"issue":"3","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.24875\/AIDSRev.M20000036","article-title":"Weight gain in HIV-infected individuals using distinct antiretroviral drugs","volume":"22","author":"Buz\u00f3n-Mart\u00edn L","year":"2020","unstructured":"Buz\u00f3n-Mart\u00edn L. Weight gain in HIV-infected individuals using distinct antiretroviral drugs. AIDS Rev. 22(3), 158\u2013167 (2020).","journal-title":"AIDS Rev."},{"issue":"4","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/09540121.2021.1935438","article-title":"Factors associated with overweight\/obesity in a cohort of people living with HIV over 50 years of age","volume":"34","author":"Mazzitelli M","year":"2022","unstructured":"Mazzitelli M, Isabel Pereira B, Moyle G Factors associated with overweight\/obesity in a cohort of people living with HIV over 50 years of age. AIDS Care 34(4), 542\u2013544 (2022).","journal-title":"AIDS Care"},{"issue":"3","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/aid.2021.0091","article-title":"Integrase inhibitor use associated with weight gain in women and incident diabetes mellitus","volume":"38","author":"Asundi A","year":"2022","unstructured":"Asundi A, Olson A, Jiang W Integrase inhibitor use associated with weight gain in women and incident diabetes mellitus. AIDS Res. Hum. Retroviruses 38(3), 208\u2013215 (2022).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/ofid\/ofy210.547","article-title":"538. Integrase inhibitor-based HAART is associated with greater BMI gains in Blacks, Hispanics, and women","volume":"5","author":"Bedimo R","year":"2018","unstructured":"Bedimo R, Adams-Huet B, Taylor B, Lake J, Luque A. 538. Integrase inhibitor-based HAART is associated with greater BMI gains in Blacks, Hispanics, and women. Open Forum Infect. Dis. 5(S1), S199 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"e_1_3_5_16_2","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (updated September 21 2022). https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (October 5 2022)."},{"issue":"1","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard AR","year":"2020","unstructured":"Eckard AR, Mccomsey GA. Weight gain and integrase inhibitors. Curr. Opin. Infect. Dis. 33(1), 10\u201319 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"8","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/03007995.2020.1775074","article-title":"An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus","volume":"36","author":"Chow W","year":"2020","unstructured":"Chow W, Donga P, C\u00f4t\u00e9-Sergent A An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr. Med. Res. Opin. 36(8), 1313\u20131323 (2020).","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/03007995.2021.2007006","article-title":"Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide or bictegravir\/emtricitabine\/tenofovir alafenamide in the United States","volume":"38","author":"Emond B","year":"2022","unstructured":"Emond B, Rossi C, Cote-Sergent A Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide or bictegravir\/emtricitabine\/tenofovir alafenamide in the United States. Curr. Med. Res. Opin. 38(2), 287\u2013298 (2022).","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi K","year":"2020","unstructured":"Bourgi K, Jenkins CA, Rebeiro PF Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J. Int. AIDS Soc. 23(4), e25484 (2020).","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"ofaa619","DOI":"10.1093\/ofid\/ofaa619","article-title":"Integrase strand transfer inhibitors play the main role in greater weight gain among men with acute and early HIV infection","volume":"8","author":"Wu KS","year":"2021","unstructured":"Wu KS, Anderson C, Little SJ. Integrase strand transfer inhibitors play the main role in greater weight gain among men with acute and early HIV infection. Open Forum Infect. Dis. 8(1), ofaa619 (2021).","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood J","year":"2017","unstructured":"Norwood J, Turner M, Bofill C Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J. Acquir. Immune. Defic. Syndr. 76(5), 527 (2017).","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"issue":"8","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","DOI":"10.3390\/v14081677","article-title":"Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug","volume":"14","author":"Pantazis N","year":"2022","unstructured":"Pantazis N, Papastamopoulos V, Antoniadou A Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug. Viruses 14(8), (2022).","journal-title":"Viruses"},{"issue":"28","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin PC","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"issue":"25","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"issue":"7","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi K","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin. Infect. Dis. 70(7), 1267\u20131274 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.36469\/jheor.2020.13457","article-title":"Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors","volume":"7","author":"Chen YW","year":"2020","unstructured":"Chen YW, Hardy H, Pericone CD, Chow W. Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors. J. Health Econ. Outcomes Res. 7(2), 102\u2013110 (2020).","journal-title":"J. Health Econ. Outcomes Res."},{"issue":"11","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1089\/aid.2020.0287","article-title":"Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States","volume":"37","author":"Mounzer K","year":"2021","unstructured":"Mounzer K, Brunet L, Hsu R Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. AIDS Res. Hum. Retroviruses 37(11), 852\u2013861 (2021).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"8","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/biomedicines10081823","article-title":"Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis","volume":"10","author":"Mazzitelli M","year":"2022","unstructured":"Mazzitelli M, Trunfio M, Putaggio C Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis. Biomedicines 10(8), 1823 (2022).","journal-title":"Biomedicines"},{"issue":"2","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1097\/QAD.0000000000003092","article-title":"Weight gain stopping\/switch rules for antiretroviral clinical trials","volume":"35","author":"Venter WDF","year":"2021","unstructured":"Venter WDF, Sokhela S, Calmy A Weight gain stopping\/switch rules for antiretroviral clinical trials. AIDS 35(Suppl. 2), S183\u2013S188 (2021).","journal-title":"AIDS"},{"issue":"2","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10461-020-03022-w","article-title":"Heart health and behavior change in HIV-infected individuals","volume":"25","author":"Abbamonte JM","year":"2021","unstructured":"Abbamonte JM, Cristofari NV, Weiss SM, Kumar M, Jayaweera DT, Jones DL. Heart health and behavior change in HIV-infected individuals. AIDS Behav. 25(2), 615\u2013622 (2021).","journal-title":"AIDS Behav."},{"key":"e_1_3_5_32_2","unstructured":"HIV by Group. www.cdc.gov\/hiv\/group\/index.html (2022)."},{"issue":"9","key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy","volume":"71","author":"Lake JE","year":"2020","unstructured":"Lake JE, Wu K, Bares SH Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy. Clin. Infect. Dis. 71(9), e471\u2013e477 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax PE","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin. Infect. Dis. 71(6), 1379\u20131389 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_5_35_2","first-page":"8","article-title":"Weight gain post-ART in HIV+ Latinos\/as differs in the USA, Haiti, and Latin America","author":"Coelho LE","year":"2022","unstructured":"Coelho LE, Jenkins CA, Shepherd BE Weight gain post-ART in HIV+ Latinos\/as differs in the USA, Haiti, and Latin America. The Lancet Regional Health \u2013 Americas 8 (2022).","journal-title":"The Lancet Regional Health \u2013 Americas"},{"issue":"1","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36469\/30184","article-title":"Real-world assessment of weight change in African American females and Hispanics with HIV-1 after initiating integrase strand-transfer inhibitors or protease inhibitors","volume":"9","author":"Chen Y-W","year":"2022","unstructured":"Chen Y-W, Anderson D, Pericone CD, Donga P. Real-world assessment of weight change in African American females and Hispanics with HIV-1 after initiating integrase strand-transfer inhibitors or protease inhibitors. J. Health Econ. Outcomes Res. 9(1), 1\u201310 (2022).","journal-title":"J. Health Econ. Outcomes Res."},{"issue":"6","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2902","article-title":"Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis","volume":"33","author":"Nduka CU","year":"2017","unstructured":"Nduka CU, Stranges S, Kimani PK, Sarki AM, Uthman OA. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab. Res. Rev. 33(6), (2017).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar S","year":"2018","unstructured":"Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front. Endocrinol. (Lausanne) 9, 705 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"e_1_3_5_39_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","article-title":"Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals","volume":"73","author":"Herrin M","year":"2016","unstructured":"Herrin M, Tate JP, Akgun KM Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J. Acquir. Immune Defic. Syndr. 73(2), 228\u2013236 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"10","key":"e_1_3_5_40_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"Mccann K","year":"2021","unstructured":"Mccann K, Shah S, Hindley L Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS 35(10), 1657\u20131665 (2021).","journal-title":"AIDS"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-022-00673-1","article-title":"Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy","author":"Mccomsey GA","year":"2022","unstructured":"Mccomsey GA, Emond B, Shah A Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy. Infect. Dis. Ther. doi:10.1007\/s40121-022-00673-1 (2022) (Epub ahead of print).","journal-title":"Infect. Dis. Ther."},{"issue":"5","key":"e_1_3_5_42_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QAI.0000000000002603","article-title":"Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in hiv-positive individuals: results from the D:A:D Study","volume":"86","author":"Petoumenos K","year":"2021","unstructured":"Petoumenos K, Kuwanda L, Ryom L Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in hiv-positive individuals: results from the D:A:D Study. J. Acquir. Immune Defic. Syndr. 86(5), 579\u2013586 (2021).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_5_43_2","unstructured":"A study of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) evaluated as a fixed dose combination regimen in participants switching from an integrase inhibitor who have experienced rapid weight gain (DEFINE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04442737 (2022)."},{"key":"e_1_3_5_44_2","unstructured":"Doravirine for persons with excessive weight gain on integrase inhibitors and tenofovir alafenamide. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04636437 (2022)."},{"issue":"9","key":"e_1_3_5_45_2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter WDF","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N. Engl. J. Med. 381(9), 803\u2013815 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_5_46_2","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study","volume":"24","author":"Mallon PW","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J. Int. AIDS Soc. 24(4), e25702\u2013e25702 (2021).","journal-title":"J. Int. AIDS Soc."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T04:42:55Z","timestamp":1701492175000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/cer-2022-0147"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0147","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"cer-2022-0147"}}